HEILBRONN (GERMANY) & BARCELONA - 23 June 2026 – SLK-Kliniken Heilbronn GmbH in collaboration with the MOLIT Institute for PersonalizedMedicine, and Omniscope, a techbio company in systems immunology, today announced a partnership to integrate proprietary high-resolution immune profiling and generative AI for therapeutic design and to improve healthspan. By combining deep cellular immune profiling with AI-driven modeling, the partnership enables a “Cellular Avatar”: a dynamic computational model of an individual’s immune system used to track health trajectories over time and inform personalized care.
Reading the Immune System: Cellular Avatar
At the center of the collaboration is Omniscope’s ability to move beyond static, single-timepoint blood tests. Using its osLifetime platform, Omniscope decodes the immune system at cellular resolution to create personalized AI to models of dynamics of an individual’s immune activity, generating a Cellular Avatar that can be tracked longitudinally.
This provides customers an insight to their cellular state: a way to observe how your immune system is responding to aging, environmental stressors, disease, as well as to tailor interventions such as exercise, supplementation and therapy to each person’s biological signature rather than to population averages. This means your actions are informed by your biology coupled with security and data sovereignty.
Omniscope´s osLifetime was developed with Barça Innovation Hub, and used by elite athletes at Football Club Barcelona, to prevent injury and enhance player longevity.
From the Tumor Board to the Prevention Board
What distinguishes this partnership is its clinical and scientific foundation. Unlike a conventional longevity offering, the program is anchored in an established cancer center and a dedicated translational research institute. SLK’s oncology expertise is paired with the MOLIT Institute for Personalized Medicine, whose work spans molecular tumor boards, health-data interoperability, andAI-supported clinical decision-making.
Building on its molecular tumor board, the team is developing a “prevention board”: a multidisciplinary framework that integrates Omniscope’s immune intelligence with complementary data — including microbiome, nutrition, body composition, laboratory results, and activity — to support a holistic, longitudinal view of health. The aim is a genuinely translational pathway, from science to the healthcare system.
A Focus on Survivorship and Healthy Aging
Advances in therapeutics and healthcare mean more people are living longer. The question is living longer healthier lives- including beyond a cancer diagnosis. How those survivors age — their cardiovascular, metabolic, and immune health over the following five, ten, and more years — is becoming a central clinical question. By extending immune monitoring to cancer survivors, and to the wider population pursuing healthy aging, the partnership reframes “longevity” in concrete, scientifically grounded terms.
Prof. Dr. med. Dr. h.c. Uwe Martens, Clinic Director, SLK-Kliniken; Co-Founder, MOLIT Institute for Personalized Medicine
“Our vision is to move from science to the bedside, andfrom the bedside into everyday healthcare. We are experts in cancer care, butour responsibility does not end when the cancer is gone: it extends to how ourpatients live and age in the years that follow. Our vision is to preventdisease in healthy populations.
Bringing Omniscope’s immune intelligence intoour prevention board lets us understand each person’s biology more deeply, andto offer the same precision in healthy aging that we have built in oncology.”
Prof. Holger Heyn, Chief Scientific Officer, Omniscope
“For the first time, we can give customers ahigh-resolution, longitudinal view of the immune system rather than a singlesnapshot. The immune system is one of the body’s richest sources of informationabout health and disease. Through AI modeling, we can now anticipate changerather than only react to it. Working with a center of SLK’s clinical andtranslational caliber is exactly how this technology should reach everyoneinterested in taking charge of their health.”
Availability and Collaboration
The osLifetime technology is available at SLK incollaboration with the MOLIT Institute. Clinicians, researchers, andinstitutions interested in immune-repertoire monitoring and translationalcollaboration are invited to get in touch via the contacts below.
For more information, please visit www.omniscope.ai, www.molit.eu, or contact health@slk-kliniken.de
ABOUT OMNISCOPE:
Omniscope is a techbio company building the world’s most advanced immune intelligence platform. Originating from clinical immunology, Omniscope combines patented laboratory technologies, deep T and B cell receptor sequencing, and AI-driven models to generate high-resolution, dynamic insights into the immune system. Omniscope’s mission is to empower clinicians, researchers, and athletes with predictive, personalized immune data — improving diagnostics, therapeutic development, performance, and healthspan. Learn more: https://www.omniscope.ai/about-us
ABOUT SLK-KLINIKEN:The SLK-Kliniken Heilbronn GmbH network is the largest healthcare provider in the Heilbronn-Franken region and, as a municipally owned organization, stands for comprehensive healthcare: compassionate, highly professional, and equipped for the future. The Heilbronn-Franken Cancer Center is based at Klinikum am Gesundbrunnen. It comprises twelve affiliated organ cancer centres certified by the German Cancer Society (DKG), as well as integrated palliative care services and a clinical study center. This makes the Heilbronn-Franken Cancer Center one of the most modern interdisciplinary oncology facilities at municipal level inGermany. Each year, approximately 3,200 new diagnoses are made, and around5,000 patients are undergoing treatment.
ABOUT MOLIT INSTITUTE FOR PERSONALIZED MEDICINE
The MOLIT Institute teaches and conducts application-oriented research in personalized medicine. The focus is the translation of personalized medical concepts from basic research into standard medical care, their IT support, and the use of routine data in medical research. Funding from the Dieter SchwarzFoundation enables MOLIT to conduct independent research, allowing it to focus on science and the global dissemination of knowledge. The institute thereby significantly complements the forward-looking field of biomedical sciences in the Heilbronn region.
